Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment

Brain Research

Volumn 861, Issue 1, 2000, Pages 126-134

  Fornai, Francesco ^a,b   Giorgi, Filippo S ^c   Bassi, Lucia ^a   Ferrucci, Michela ^a   Alessandrì, Maria G ^b   Corsini, Giovanni U ^a  

^a UNIVERSITY OF PISA   (Italy)

^b DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^c SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Dihydroxyphenylacetaldehyde; DOPALD; Dopamine; Dopamine metabolism; L DOPA; Monoamine oxidase

Indexed keywords

2 ETHYL 1,2,3,4,6,7 HEXAHYDRO 2 HYDROXY 3 ISOBUTYL 9,10 DIMETHOXY 11BH BENZO[A]QUINOLIZINE; AMINE OXIDASE (FLAVIN CONTAINING); CLORGYLINE; DIHYDROXYPHENYLACETALDEHYDE; DOPAMINE DERIVATIVE; LAZABEMIDE; N (2 AMINOETHYL) 5 (3 FLUOROPHENYL) 4 THIAZOLECARBOXAMIDE; OXIDOPAMINE; PARGYLINE; SELEGILINE; UNCLASSIFIED DRUG; VANOXERINE;

AEROBIC METABOLISM; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR FLUID; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE UPTAKE INHIBITORS; HOMOVANILLIC ACID; LEVODOPA; MALE; MONOAMINE OXIDASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034616302     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02054-0     Document Type: Article

References (35)

1. Bunney B.S., Aghajanian G.K., Roth R.H. Comparison of effects of L-DOPA, amphetamine, and apomorphine on firing rate of rat dopaminergic neurons. Nature. 245:1973;123-125.
2. Buu N.T., Angers M. Effects of different monoamine oxidase inhibitors on the metabolism of L-DOPA in the rat brain. Biochem. Pharmacol. 36:1987;1731-1735.
3. Cesura A.M., Pletscher A. The new generation of monoamine oxidase inhibitors. Prog. Drug Res. 38:1992;171-297.
4. Cohen G. Alkaloid products in the metabolism of alcohol and biogenic amines. Biochem. Pharmacol. 25:1976;1123-1128.
5. Cohen G., Farooqui R., Kesler N. Parkinson's disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. USA. 94:1997;4890-4894.
6. Colzi A., Musolino A., Iuliano A., Fornai F., Bonuccelli U., Corsini G.U. Identification and determination of 3,4-dihydroxyphenylacetaldehyde, the dopamine metabolite, in in vivo dialysate from rat striatum. J. Neurochem. 66:1996;1510-1517.
7. Corsini G.U., Zuddas A., Bonuccelli U., Schinelli S., Kopin I.J. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol and acetaldehyde. Life Sci. 40:1987;827-832.
8. Da Prada M., Kettler R., Keller H.H., Cesura A.M., Richards J.G., Saura Marti J., Muggli-Maniglio D., Wyss P.C., Kyburz E., Imhof R. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J. Neural Transm., Suppl. 29:1990;279-292.
9. Davis V.E., Walsh M.J. Alcohol, amines and alkaloids: possible biochemical basis for alcohol addiction. Science. 167:1970;1005-1007.
10. Finberg J.P.M., Pacak K., Kopin I.J., Goldstein D.S. Chronic inhibition of monoamine oxidase type A increases noradrenaline release in the frontal cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 347:1993;500-505.
11. Finberg J.P.M., Wang J., Goldstein D.S., Kopin I.J., Bankiewicz K.S. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J. Neurochem. 65:1995;1213-1220.
12. Fornai F., Alessandrì M.G., Torracca M.T., Bassi L., Corsini G.U. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. J. Pharmacol. Exp. Ther. 283:1997;100-107.
13. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
14. T.G. Hastings, M.J. Zigmond, Loss of dopaminergic neurons in parkinsonism: possible role of reactive metabolite, in: Y. Mizuno, M.B.H. Youdim, D.B. Calne, R. Horowski, W. Poewe, P. Riederer (Eds.), Advances in Research on Neurodegeneration, Vols. 3 and 4, Springer-Verlag, Wien, 1997, pp. 103-110.
15. Hauptlorenz S., Esterbauer H., Moll W., Pumpel R., Schauenstein E., Puschendorf B. Effects of the lipid-peroxidation product 4-hydroxynonenal and related aldehydes on proliferation and viability of cultured Ehrlich ascites tumor cells. Biochem. Pharmacol. 34:1985;3803-3809.
16. Helander A., Tottmar O. Metabolism of biogenic aldehydes in isolated human blood cells, platelets and plasma. Biochem. Pharmacol. 36:1987;1077-1082.
17. Jennet R.B., Tuma D.S., Sorrel M.F. Effect of ethanol and its metabolites on microtubule formation. Pharmacology. 21:1980;363-368.
18. Juorio A.V., Paterson I.A., Zhu M.Y. Dopamine metabolism in the guinea pig striatum: role of monoamine oxidase A and B. Eur J. Pharmacol. 254:1994;213-220.
19. Kopin I.J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 37:1985;333-364.
20. Lamensdorf I., Youdim M.B.H., Finberg J.P.M. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem. 67:1996;1532-1539.
21. Maruyama W., Sobue G., Matsubara K., Hashizume Y., Dostert P., Naoi M. A dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigro-striatal system of the human brain. Neurosci. Lett. 14:1997;61-64.
22. Mattamal M.B., Chung H.D., Strong R. Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry. J. Chromatogr. 614:1993;205-212.
23. Mattamal M.B., Haring J.H., Chung H.D., Raghu G., Strong R. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration. 4:1995;271-281.
24. Miglietta A., Olivero A., Gadoni E., Gabriel L. Effects of some aldehydes on brain microtubular protein. Chem. Biol. Interact. 78:1991;183-191.
25. Naoi M., Maruyama W., Dostert P., Hashizume Y., Nakahara D., Takahashi T., Ota M. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-R-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res. 19:1996;285-295.
26. G. Paxinos, C. Watson (Eds.), The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, San Diego, 1986.
27. Perese D.A., Ulman J., Viola J., Ewing S.E., Bankiewicz K.S. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res. 273:1989;45-51.
28. Pletscher A., Brossi A., Gey K.F. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int. Rev. Neurobiol. 4:1962;275-305.
29. Sodum R.S., Chung F.L. Stereoselective formation of nucleic acid adducts by 2,3-epoxy-4-hydroxynonanal. Cancer Res. 51:1991;137-143.
30. R. Strong, W.G. Wood, W.J. Burke (Eds.), Aging, Vol. 33: Central Nervous System Disorders of Aging: Clinical Intervention and Research, Raven Press, New York, 1988.
31. B. Tabakoff, Brain aldehyde dehydrogenases and reductases, in: N. Weaver, M.B.H. Youdim (Eds.), Biochemistry and Function of Monoamine Enzymes, Marcell Dekker, New York, 1977, pp. 629-649.
32. K.F. Tipton, T.J. Mantle, The inhibition of rat liver monoamine oxidase by clorgyline and deprenyl, in: M.B.H. Youdim, E.S. Paikel (Eds.), Monoamine Oxidase Inhibitors. The State of Art, Wiley, New York, 1981, pp. 3-15.
33. Westlund K.N., Denney R.M., Kochersberger L.M. Distinct monoamine oxidase A and B populations in primate brain. Science. 230:1985;181-183.
34. Westlund K.N., Krakower T.J., Kwan S.-W., Abell C.W. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res. 612:1993;221-230.
35. Zetterstrom T., Sharp T., Collin A.K., Ungerstedt U. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs. Implication for the origin of extracellular DOPAC. Eur. J. Pharmacol. 148:1988;327-334.